Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy

Learn more about:
Related Clinical Trial
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy

Official Title

A Controlled Open Label Phase II Study Assessing the Efficacy of Intracoronary Autologous Mesenchymal Stem Cells in Patients With Ischemic Dilated Cardiomyopathy

Brief Summary

      Despite the recent advances in medical and surgical treatment, heart failure resulting from
      ischemic cardiomyopathy (ICM) remains the leading cause of cardiovascular mortality. Ischemic
      dilated cardiomyopathy(ICM) is defined as abnormally enlarged left ventricular (LV) cavity
      with documented poor LV function as a result of severe coronary artery disease (CAD). LV
      remodelling which is inevitable after an infarct has been postulated to contribute largely to
      the poor outcome of patients with ICM, therefore prevention of LV remodelling is the goal for
      the treatment in patients with severe CAD. Cell therapy represents a novel therapeutic
      strategy for treating cardiac diseases including severe CAD and heart failure. A type of stem
      cells known as mesenchymal stem cells(MSCs)can be isolated from bone marrow.This study aims
      to test the differentiation potential and therapeutic capacity of MSC from severe CAD
      patients after intracoronary implantation in an ischemic myocardial environment in Malaysian
      population.
    

Detailed Description

      Ischemic dilated cardiomyopathy(ICM) is defined as abnormally enlarged left ventricular (LV)
      cavity with documented poor LV function as a result of severe coronary artery disease (CAD).
      LV remodelling which is inevitable after an infarct has been postulated to contribute largely
      to the poor outcome of patients with ICM, therefore prevention of LV remodelling is the goal
      for the treatment in patients with severe CAD. Cell therapy represents a novel therapeutic
      strategy for treating cardiac diseases including severe CAD and heart failure. A type of stem
      cells known as mesenchymal stem cells(MSCs)can be isolated from bone marrow. Experimental and
      clinical studies to date have shown that mesenchymal stem cells represent the most suitable
      cell type for regeneration therapy after myocardial infarction (MI). After injection into
      ischemic myocardium, bone marrow-derived MSC (BM-MSC) from various animal species can
      differentiate into multiple cell lineages, including endothelial cells and cardiomyocytes,
      thereby improving LV function.

      In Malaysia we have previously demonstrated our capability in isolating and extracting MSC
      from a small volume of bone marrow aspirates.The isolation, expansion and feasibility of
      storage, transport and differentiation of human MSC for clinical application has been
      performed locally. The researchers used autologous BM-MSC, ex vivo expanded, on three
      patients with end-stage ischemic dilated cardiomyopathy who were on the heart transplant
      waiting list and each patient was injected with MSCs directly into the myocardium during open
      heart surgery. After twelve months, all patients remained alive and well with significant
      improvement in cardiac function, quality of life and other parameters including reduction of
      myocardial scar volume as seen from cardiac scans.

      The same group of researchers further carried out a study on ten patients with severe dilated
      cardiomyopathy and refractory cardiac function despite maximum medical therapy to receive
      autologous BM-MSC implantation via intramyocardial or intracoronary route. All patients
      remained alive at 1 year while recorded significant improvements in LV ejection fraction and
      other LV parameters from baseline to 6 and 12 months. Reduction in scar was also noted in six
      of the patients by 12 months.

      Following these results, this study aims to test the differentiation potential and
      therapeutic capacity of MSC from severe CAD patients after intracoronary implantation in an
      ischemic myocardial environment in Malaysian population.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation

Secondary Outcome

 Changes in functional status

Condition

Ischemic Dilated Cardiomyopathy

Intervention

BM-MSCs

Study Arms / Comparison Groups

 Maximal medical therapy
Description:  Maximal medical therapy which comprises of optimal pharmacological therapy

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

80

Start Date

July 2012

Completion Date

December 2015

Primary Completion Date

December 2015

Eligibility Criteria

        Inclusion Criteria:

          -  aged between 35 to 75 years

          -  diagnosed to have ICM confirmed by previous coronary angiogram showing significant
             coronary artery disease >70% or history of previous myocardial infarction.

          -  myocardial infarction event occured 6 months or longer from time of screening.

          -  LV ejection fraction of ≤40% by echocardiogram or cardiac MRI.

        Exclusion Criteria:

          -  Likelihood of heart failure from other causes such as idiopathic, infective or
             metabolic cardiomyopathy,valvular heart disease and pericardial disease.

          -  patients who had undergone a coronary artery bypass graft(CABG) procedure.

          -  patients who do not have any visible/significant myocardial scar.

          -  patients with any cardiovascular metallic implantation.

          -  any contraindication to bone marrow aspiration

          -  any contraindication to coronary contrast angiography and angioplasty.

          -  any acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV.

          -  any past history of neoplasia and primary haematological disease.

          -  any current, past or paroxysmal cardiac arrhythmias.

          -  renal impairment indicated by creatinine clearance of less than 30 ml/min.

          -  liver impairment indicated by serum alanine transferase level at 4 times greater than
             normal value.
      

Gender

All

Ages

35 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Oteh Maskon, MB Bch, , 

Location Countries

Malaysia

Location Countries

Malaysia

Administrative Informations


NCT ID

NCT01720888

Organization ID

ERGS/1/2011/SKK/UKM/02/72


Responsible Party

Principal Investigator

Study Sponsor

National University of Malaysia

Collaborators

 Cytopeutics Sdn. Bhd.

Study Sponsor

Oteh Maskon, MB Bch, Principal Investigator, Universiti Kebangsaan Malaysia Medical Centre


Verification Date

April 2015